Академический Документы
Профессиональный Документы
Культура Документы
Collection of companies that research, create, and market generic and brand-
name pharmaceuticals, medical devices, and OTC drug products
The global pharmaceuticals market is worth US$300 billion a year expected
to increase to US$400 billion with 3 years
Drug sales to pharmacies (89%)
11% sales in hospitals (buy drugs from manufacturers)
Drug spending:
o 42% by government
o remainder through private insurance companies and cashpayers
Most Canadians have insurance (public or private insurance company), for
those whose drugs are not covered, people paying out of pocket
56 Pharma companies, 10th largest market sales in the world, 6.8% market
growth 2015, 26, 301 employees, 110, 849 prescribers
Shire recently acquired Vaxolta, as a result, company is moving to Toronto;
right now based outside Montreal
2015: 7% growth
Federal/National Responsibilities
o Health Canada market authorization
o Patented Medicines Pricing Review Board pricing regulator
o Common Drug Review HTA review (look at clinical data and
determine whether drug will be reimbursed for Canadians)
Probably number one challenge: difference between access and
no access; not everyone has private insurance; number of
individuals rely on provincial reimbursement outweigh those that
have private insurance
More difficult for CDR to provide a positive recommendation
Provincial
o Provinces independent review of drugs and determine reimbursement
o PCPA Pan-Canada Pricing Alliance
Independent but links with CDR; if CDR comes with negative
recommendation, individual provinces through PCPA have ability
and authority to reimburse and make decision to reimburse drug
for that province
o Province delivers healthcare (budget) (doctors, hospitals, drugs)
Canadian pharmaceutical environment: universal healthcare for all free
access to physicians
98% of Canadians have drug coverage; drugs are funded through both
private insurers and public health systems
Improving IP System
A relatively predictable regulatory and reimbursement environment
Strong clinical science early clinical research through post-marketing
studies
Johnson and Johnson massive entity with several companies that fall under
umbrella
o One company is Janson (has drug with most revenue)
o Remecade for arthritis
Novatris, Treva/Cobalt/Actavis, Apotex, Gilead, Pfizer/Hospira